Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 2,510 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: RAPID Clear all

Conditions: 3rd Line GIST
Interventions: STI571, BKM120; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Boston, Massachusetts • Seattle, Washington

Conditions: Healthy
Interventions: rTMS; Device
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Inflammatory Bowel Disease, Crohn Disease
Interventions: Coronal T1 weighted spin echo images, Spin-lattice relaxation (T1), Magnetic resonance spectroscopy, Blood Draw; Diagnostic Test
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 13 Years to 20 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Intubation Complication
Interventions: Etomidate, Ketamine; Drug
Lead sponsor: South East Area Health Education Center, Wilmington, NC; Other
Eligibility: 18 Years and older
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Ewing Sarcoma
Interventions: LX-101; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 10 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2033
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Long COVID, Brain Fog, Cognitive Impairment, Cognitive Dysfunction, Post-Acute COVID-19 Syndrome
Interventions: Processing Speed Training, In-lab Instrumental Activities of Daily Living Training, In-lab Brain Health Training, Transfer Package, Follow Up Phone Calls, Vocational Rehabilitation, Peer Mentoring, Reaction Time Training, Trans-auricular Vagus Nerve Stimulation: High Intensity, Trans-auricular Vagus Nerve Stimulation: Low Intensity; Behavioral · Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pharmacokinetics
Interventions: Placebo, Ergothioneine, 25 miligrams, Ergothioneine, 25 miligrams, daily for 1 week; Dietary Supplement
Lead sponsor: Natural Immune Systems Inc; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Klamath Falls, Oregon

Conditions: Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, Metastatic Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Acinar Cell Carcinoma
Interventions: ART0380, Gemcitabine, Irinotecan; Drug
Lead sponsor: Artios Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 46
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 37 more

Conditions: Adenovirus Infection, Epstein-Barr Virus Infections, Cytomegalovirus Infections, Stem Cell Transplant
Interventions: Multi-virus Specific T cells; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Non Small Cell Lung Cancer
Interventions: Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation; Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: New York, New York

Conditions: Childhood Cancer Survivors
Interventions: prolonged overnight fasting, usual care; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19, Endothelial Function
Interventions: Vascular occlusion test; Device
Lead sponsor: Corporacion Parc Tauli; Other
Eligibility: 18 Years and older
Enrollment: 612 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pain, Fracture, Sprain
Interventions: Fentanyl, Lansoprazole, Oxycodone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Normal Subjects
Interventions: Rabeprazole; Drug
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 1 Diabetes Mellitus
Interventions: HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100 U/ml), Mandated back ground therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 99
States / cities: Little Rock, Arkansas • Concord, California • Escondido, California + 80 more

Conditions: Multi-drug Resistant Tuberculosis
Interventions: Pretomanid; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Glycemia
Interventions: Berberine, Dihydroberberine 200, Dihydroberberine 100, Placebo; Dietary Supplement
Lead sponsor: Lindenwood University; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Subacute Low Back Pain
Interventions: Progressive Exercise Plan, NeuromuscularElectricalStimulation(NMES), Primary Care Management (PCM); Behavioral · Device
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years to 45 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Fort Campbell North, Kentucky

Conditions: Acute Myeloid Leukemia
Interventions: Venetoclax, Daunorubicin, Cytarabine; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois • Boston, Massachusetts

Conditions: Circulatory Failure, Cardiac Arrest
Interventions: rapid pulse confirmation device; Device
Lead sponsor: Michael Kyle Ritchie; Other
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Screening Breast MRI in Patients Who Are BRCA Mutation Carriers
Interventions: MRI, Optional Screening Questionnaire; Device · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 30 Years and older · Female only
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Congestive Heart Failure, Cardiomyopathy, Dyspnea, Pulmonary Edema, Heart Diseases
Interventions: Fluid Status Monitoring (OptiVol™); Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 12
States / cities: Anchorage, Alaska • Atlantis, Florida • Fort Wayne, Indiana + 9 more

Conditions: Covid19
Interventions: Saliva test kit; Device
Lead sponsor: Stanford University; Other
Eligibility: 2 Years and older
Enrollment: 1,277 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Pleasanton, California • Stanford, California

Conditions: Healthy Volunteers
Interventions: Fast release BRB confection, Intermed release BRB confection, Prolong release BRB confection; Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients

Metaplasticity Experimental Design and Comparison of Motor Outcome Measure Sensitivity to Change

Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease

Evaluating the Hemodynamic Effects of Ketamine Versus Etomidate During Rapid Sequence Intubation

RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT

Long COVID Brain Fog: Cognitive Rehabilitation Trial

Clinical Study on Rapid Antioxidant Protection and Immune Modulating Effects.

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)

Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients

Overnight Fasting After Completion of Therapy: The OnFACT Study

Non-invasive Characterization of Systemic Microvascular Reactivity by Near-infrared Diffuse Optical Spectroscopy in COVID-19 Patients

Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain

Rabeprazole Protection of Aspirin Induced Gastric Damage.

A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus

Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid

Bioavailability of Berberine and Dihydroberberine and Their Impact on Glycemia

Subacute Low Back Pain in Active Duty

Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML

Evaluation of Efficacy of the Prototype RPC (Rapid Pulse Confirmation) Device in Detecting Return of Pulsatile Flow in Patients Preparing to Separate From CPB (Cardiopulmonary Bypass)

Rapid Pancreatic and Ovarian Screening MR Imaging With Motion Corrected T1, T2, and Advanced Diffusion Weighted Imaging for Patients With BRCA Mutation Who Undergo Screening Breast MRI

FAST (Fluid Accumulation Status Trial)

Rapid Turnaround, Home-based Saliva Testing for COVID-19

Black Raspberry Confection in Preventing Oral Cancer in Healthy Volunteers